14 January 2024: Articles
Adjunctive Intravenous Immunoglobulin and Glucocorticoid Therapy in Severe Herpes Simplex Encephalitis with Excellent Outcome Begs for Larger Trials Evaluating Immunomodulatory Therapy
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Clinical situation which can not be reproduced for ethical reasons
George Sakoulas A* , Jon Roth A , Hugo Van der Kuy BDOI: 10.12659/AJCR.941864
Am J Case Rep 2024; 25:e941864
Figure 2. Case report timeline highlighting: i) early initiation of IVIG and methylprednisolone; ii) continuation of acyclovir beyond the usual 21 days due to persistently positive HSV-1 PCR in CSF; iii) the development of NMDA-receptor antibodies requiring more immunomodulation at 6 weeks. IVIG – intravenous immunoglobulin G; HSV-1 – herpes simplex virus 1; PCR – polymerase chain reaction; CSF, cerebrospinal fluid; NMDA – N-methyl-D-aspartate.